Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

PURPOSE Recent molecular data have suggested that non-neoplastic cells are powerful modulators that may confer a selective advantage or disadvantage on the outcome of follicular lymphoma (FL) patients. PATIENTS AND METHODS The prevalence of the principal inflammatory and immune-infiltrated cells was measured immunohistochemically in the tissue of 211 FL patients, and associations were sought with their traditional clinicobiologic characteristics. RESULTS Our results confirmed the presence of a large number of T lymphocytes (CD4+ and CD8+) and CD57+ cells and, at a moderate level, the presence of TIA-1+ cytotoxic cells, CD68+ macrophages, CD123+ plasmacytoid cells, and FOXP3+ regulatory T cells among the pool of non-neoplastic cells. In addition to the conventional clinical variables, univariate analysis identified a low level of infiltrated CD8+ T lymphocytes as a significantly negative prognostic factor of overall survival. The following significant differences in the abundance of cells of specific and nonspecific immunity were observed in relation to the clinicobiologic features of FL: (1) a reactive microenvironment mainly made up of T lymphocytes and macrophages was significantly associated with a favorable clinical behavior of FL patients; and (2) a reactive microenvironment infiltrated predominantly by CD57+ T cells was associated with a significantly higher frequency of adverse clinicobiologic manifestations such as "B" symptoms and bone marrow involvement. CONCLUSION Our results demonstrate the existence of two specific patterns in the reactive microenvironment of FL, an immunosurveillance pattern (T lymphocytes and macrophages) and an immune-escape pattern (CD57+ T cells), that were directly associated with the clinicobiologic features of these patients.

[1]  L. Medeiros,et al.  Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell types. , 2003, The American journal of pathology.

[2]  Fiona Powrie,et al.  Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.

[3]  J. Gerdes,et al.  The human germinal centre cells, follicular dendritic cells and germinal centre T cells produce B cell-stimulating cytokines. , 1995, Cytokine.

[4]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[5]  T. Grogan,et al.  Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas , 2003, Laboratory Investigation.

[6]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[7]  R. Warnke,et al.  Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression. , 1988, American journal of clinical pathology.

[8]  Xuelin Huang,et al.  Germinal centre‐like versus undifferentiated stromal immunophenotypes in follicular lymphoma , 2003, The Journal of pathology.

[9]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[10]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[11]  W. Chan,et al.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. , 1995, Blood.

[12]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[13]  A. Wotherspoon,et al.  Relative distribution of tumour cells and reactive cells in follicular lymphoma , 2001, The Journal of pathology.

[14]  Marylène Lejeune,et al.  Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients , 2005, Leukemia & lymphoma.

[15]  J. Gribben,et al.  In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation , 1997 .

[16]  T. Veenstra,et al.  Fully automated synthesis of (phospho)peptide arrays in microtiter plate wells provides efficient access to protein tyrosine kinase characterization , 2005, BMC Immunology.

[17]  E. Heinen,et al.  Human Germinal Center CD4+ CD57+ T Cells Act Differently On B Cells Than Do Classical T-Helper Cells , 1995, Developmental immunology.

[18]  S. Kang,et al.  Human CD57+ germinal center-T cells are the major helpers for GC-B cells and induce class switch recombination , 2005, BMC Immunology.

[19]  O. Danos,et al.  Regulatory function of in vivo anergized CD4+ T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Warnke,et al.  T-lymphocyte subsets in follicular lymphomas compared with those in non-neoplastic lymph nodes and tonsils. , 1982, Human pathology.

[21]  S. Ingvarsson,et al.  Germinal Centers Regulate Human Th2 Development1 , 2003, The Journal of Immunology.

[22]  R. Stahel,et al.  T‐cell derived cytokines co‐stimulate proliferation of CD40‐activated germinal centre as well as follicular lymphoma cells , 1997, Hematological oncology.

[23]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Bende,et al.  In situ analysis of the variable heavy chain gene of an IgM/IgG-expressing follicular lymphoma: evidence for interfollicular trafficking of tumor cells. , 2002, The American journal of pathology.

[25]  Prof. Dr. med. Alfred Christian Feller,et al.  Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas , 2012, Springer Berlin Heidelberg.

[26]  M. Piris,et al.  FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma , 2005, Leukemia.

[27]  D. Jong.  Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors , 2005 .

[28]  R. Küppers,et al.  Tumor cell dissemination in follicular lymphoma. , 2002, Blood.

[29]  H. Masoudi,et al.  The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL) , 2006 .

[30]  R. Küppers.  Prognosis in follicular lymphoma--it's in the microenvironment. , 2004, The New England journal of medicine.

[31]  L. Esserman,et al.  Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. , 1990, Journal of immunology.

[32]  R. Bende,et al.  Variable heavy-chain gene analysis of follicular lymphomas: subclone selection rather than clonal evolution over time. , 2001, Blood.

[33]  A. Butch,et al.  Cytokine expression by germinal center cells. , 1993, Journal of immunology.

[34]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Hillsamer,et al.  Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. , 2004, The Journal of clinical investigation.

[36]  I. Lauder,et al.  A retrospective study of follicular lymphomas , 1989, Histopathology.

[37]  David Botstein,et al.  Variation in gene expression patterns in follicular lymphoma and the response to rituximab , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Peter Joosten,et al.  Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.

[39]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[40]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[41]  S. Tomoyasu,et al.  Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. , 2003, Pathology, research and practice.